Companies / Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc.
Financials
Ownership
76.3M shares outstanding · as of Jul 23, 2026
Ownership
| Insiders | 0.60% | 454,864 |
| 10%+ / strategic | 7.15% | 5,451,800 |
| Institutions | 96.93% | 73,957,289 |
| Public float | 0.00% | 0 |
Reported holdings exceed shares outstanding — public float shown as 0; some positions may overlap or lag.
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 5
View all →| Insider | % of shares | Shares |
|---|---|---|
Gould Robert JDirector | 0.60% | 454,864 |
Musso Alan AChief Financial Officer | — | — |
Oltmans Curtis GaleChief Legal Officer | — | — |
Sapir AlexSee Remarks · Director | — | — |
Tourangeau GregPrincipal Accounting Officer | — | — |
Institutional holders 183
View all →| Holder | Value | % of shares |
|---|---|---|
| $74.21M | 8.60% | |
| $59.38M | 6.88% | |
| $48.56M | 5.63% | |
| $46.43M | 7.93% | |
| $40.26M | 4.67% | |
| $34.62M | 4.01% | |
| $32.30M | 11.57% | |
| $27.12M | 3.14% | |
| $22.05M | 2.56% | |
| $21.41M | 2.48% |
Activity
InsidersInstitutions
What insiders are doing in this stock (Form 4).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Jan 2, 2026 | Gould Robert J Director | Sell | Common Stock | $178.1K | -15K -3.09% | 469,864 0.62% of shares | medium |
| Jan 2, 2026 | Gould Robert J Director | Sell | Common Stock | $163.1K | -15K -3.09% | 469,864 0.62% of shares | medium |
| Feb 2, 2026 | Gould Robert J Director | Sell | Common Stock | $160.9K | -15K -3.19% | 454,864 0.60% of shares | medium |
| Feb 2, 2026 | Oltmans Curtis Gale Executive | Grant | Stock Option (right to buy) | — | +170K | 170,000 0.22% of shares | low |
| Feb 2, 2026 | Sapir Alex Executive | Grant | Stock option - Right to Buy | — | +650K | 650,000 0.85% of shares | low |
| Feb 2, 2026 | Tourangeau Greg Executive | Grant | Stock Option (right to buy) | — | +57K | 57,000 0.07% of shares | low |
| Feb 2, 2026 | Musso Alan A Executive | Grant | Stock Option (right to buy) | — | +170K | 170,000 0.22% of shares | low |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| Vanguard Group Inc | Passive13G/A | — |
| RA Capital Management, L.P. | Passive13G/A | — |
| Tang Capital Management, LLC | Passive13G | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| FULC | — | 359616109 |